Sonnet Biotherapeutics Holdings Inc (SONN) FinancialsSONNFinancialSonnet Biotherapeutics Holdings Inc

Sonnet Biotherapeutics Holdings Inc (SONN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Better Burgers Fast Casual, accounting for 60.3% of total sales, equivalent to $5.82M. Other significant revenue streams include Hooters Full Service and Just Fresh Fast Casual. Understanding this composition is critical for investors evaluating how SONN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Sonnet Biotherapeutics Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1584.41%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SONN converts its operational activities into shareholder value.

In the context of the broader market, SONN competes directly with industry leaders such as BOLD and ELUT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SONN's gross margin of N/A stands against BOLD's N/A and ELUT's 57.87%. Such benchmarking helps identify whether Sonnet Biotherapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.